The apoptotic and autophagic properties of two natural occurring prodrugs, hyperoside and hypoxoside, against pancreatic cancer cell lines

被引:30
作者
Boukes, Gerhardt J. [1 ]
van de Venter, Maryna [1 ]
机构
[1] Nelson Mandela Metropolitan Univ, Dept Biochem & Microbiol, Med Plant & Nat Prod Res Grp, POB 77000, ZA-6031 Port Elizabeth, South Africa
基金
新加坡国家研究基金会;
关键词
Hypoxoside; Hyperoside; INS-1; MIA PaCa-2; Apoptosis; Autophagy; SORPTION ENRICHMENT; METABOLITES; IDENTIFICATION; GEMCITABINE; ROOPEROL; SURVIVAL; FUTURE;
D O I
10.1016/j.biopha.2016.07.029
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pancreatic cancer is only the 12th most common cancer, but the fourth leading cause of cancer-related deaths in the world. This is due to late prognosis, poor response to chemotherapy and early metastases. Natural prodrugs may play an important role in the treatment of pancreatic cancer. The main aim of this study was to determine the cytotoxicity of five natural prodrugs, namely harpagoside, hyperoside, hypoxoside, oleuropein and polydatin, by investigating apoptosis and autophagy as possible mechanism/s of action. Hypoxoside and hyperoside have shown selective cytotoxicity at IC50 values of similar to 25 and 50 mM against INS-1 and MIA PaCa-2 pancreatic cancer cells, respectively. Hypoxoside and hyperoside induced G2/M phase arrest and caspase-3 activation in INS-1 and MIA PaCa-2 cells, respectively. Hoechst/phalloidin staining confirmed morphological changes, including condensed chromatin multinucleation, membrane blebbing and loss of cytoskeletal arrangement in INS-1 and MIA PaCa-2 cells. Acridine orange staining was absent in INS-1 (hypoxoside) and MIA PaCa-2 (hyperoside) treated cells, whereas LC3B expression was not significantly increased. INS-1 and MIA PaCa-2 treated cells favour the cell death pathway, apoptosis, over the cell survival pathway, autophagy. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:617 / 626
页数:10
相关论文
共 42 条
  • [1] ALBRECHT CF, 1995, S AFR MED J, V85, P853
  • [2] The Flavonoid Quercetin Inhibits Pancreatic Cancer Growth In Vitro and In Vivo
    Angst, Eliane
    Park, Jenny L.
    Moro, Aune
    Lu, Qing-Yi
    Lu, Xuyang
    Li, Gang
    King, Jonathan
    Chen, Monica
    Reber, Howard A.
    Go, Vay Liang W.
    Eibl, Guido
    Hines, Oscar J.
    [J]. PANCREAS, 2013, 42 (02) : 223 - 229
  • [3] ESTABLISHMENT OF 2-MERCAPTOETHANOL-DEPENDENT DIFFERENTIATED INSULIN-SECRETING CELL-LINES
    ASFARI, M
    JANJIC, D
    MEDA, P
    LI, GD
    HALBAN, PA
    WOLLHEIM, CB
    [J]. ENDOCRINOLOGY, 1992, 130 (01) : 167 - 178
  • [4] Cell Survival or Apoptosis: Rooperol's Role as Anticancer Agent
    Boukes, Gerhardt J.
    Daniels, Brodie B.
    Albrecht, Carl F.
    van de Venter, Maryna
    [J]. ONCOLOGY RESEARCH, 2009, 18 (08) : 365 - 376
  • [5] Protective role of oleuropein and its metabolite hydroxytyrosol on cancer
    Carrera-Gonzalez, M. P.
    Ramirez-Exposito, M. J.
    Mayas, M. D.
    Martinez-Martos, J. M.
    [J]. TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2013, 31 (02) : 92 - 99
  • [6] Resveratrol metabolites have an antiproliferative effect on intestinal epithelial cancer cells
    Emilia Storniolo, Carolina
    Jose Moreno, Juan
    [J]. FOOD CHEMISTRY, 2012, 134 (03) : 1385 - 1391
  • [7] Rapamycin alleviates cisplatin-induced ototoxicity in vivo
    Fang, Bin
    Xiao, Hongjun
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 448 (04) : 443 - 447
  • [8] Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro
    Fu, Ting
    Wang, Ling
    Jin, Xiang-nan
    Sui, Hai-juan
    Liu, Zhou
    Jin, Ying
    [J]. ACTA PHARMACOLOGICA SINICA, 2016, 37 (04) : 505 - 518
  • [9] Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent
    Geng, Ying
    Kohli, Latika
    Klocke, Barbara J.
    Roth, Kevin A.
    [J]. NEURO-ONCOLOGY, 2010, 12 (05) : 473 - 481
  • [10] Emerging biological therapies for pancreatic carcinoma
    Gilliam, AD
    Watson, SA
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (04): : 370 - 378